GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (FRA:2BO) » Definitions » EV-to-FCF

Serina Therapeutics (FRA:2BO) EV-to-FCF : -2.65 (As of Apr. 10, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Serina Therapeutics's Enterprise Value is €42.37 Mil. Serina Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-15.96 Mil. Therefore, Serina Therapeutics's EV-to-FCF for today is -2.65.

The historical rank and industry rank for Serina Therapeutics's EV-to-FCF or its related term are showing as below:

FRA:2BO' s EV-to-FCF Range Over the Past 10 Years
Min: -44.05   Med: -6.85   Max: -2.83
Current: -2.83

During the past 4 years, the highest EV-to-FCF of Serina Therapeutics was -2.83. The lowest was -44.05. And the median was -6.85.

FRA:2BO's EV-to-FCF is ranked worse than
100% of 465 companies
in the Biotechnology industry
Industry Median: 2.24 vs FRA:2BO: -2.83

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-10), Serina Therapeutics's stock price is €4.38. Serina Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-2.777. Therefore, Serina Therapeutics's PE Ratio (TTM) for today is At Loss.


Serina Therapeutics EV-to-FCF Historical Data

The historical data trend for Serina Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics EV-to-FCF Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
EV-to-FCF
- - - -2.54

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only - -34.43 -8.55 -5.44 -2.54

Competitive Comparison of Serina Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Serina Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Serina Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's EV-to-FCF falls into.


;
;

Serina Therapeutics EV-to-FCF Calculation

Serina Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=42.372/-15.963
=-2.65

Serina Therapeutics's current Enterprise Value is €42.37 Mil.
Serina Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-15.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Serina Therapeutics  (FRA:2BO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Serina Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.38/-2.777
=At Loss

Serina Therapeutics's share price for today is €4.38.
Serina Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.777.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Serina Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Serina Therapeutics Business Description

Traded in Other Exchanges
Address
601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics Headlines

No Headlines